Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | HTR3B | O95264 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | ACACB | O00763 | 2/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504026 | 0.92 | ACACB (0.48) | HTR3EMEN1HTR3BCYP1A2CYP2D6 | |
| SCHEMBL4504023 | 0.92 | ACACB (0.48) | HTR3EMEN1HTR3BCYP1A2CYP2D6 | |
| SCHEMBL3821840 | 0.85 | ACACB (0.44) | HTR3EMEN1HTR3BCYP1A2CYP2D6 | |
| SCHEMBL18908932 | 0.85 | ACACB (0.47) | HTR3EMEN1HTR3BCYP1A2CYP2D6 | |
| SCHEMBL23762505 | 0.83 | ACACB (0.45) | HTR3EMEN1HTR3BCYP1A2CYP2D6 | |
| SCHEMBL4509928 | 0.73 | HTR3E (0.54) | HTR3EMEN1HTR3BCYP1A2CYP2D6 | |
| SCHEMBL3820827 | 0.73 | CYP1A2 (0.47) | HTR3EMEN1HTR3BCYP1A2CYP2D6 | |
| SCHEMBL30455678 | 0.73 | ACACB (0.40) | ACACB | |
| SCHEMBL3820910 | 0.73 | GRM2 (0.45) | HTR3EMEN1HTR3BCYP1A2CYP2D6 | |
| SCHEMBL1351805 | 0.73 | HTR3E (0.60) | HTR3EMEN1HTR3BCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603899-B1 | HETEROCYCLIC UREA DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LTD (GB) | 2009-08-26 | — | — | EP | disclosed |
| US-7528151-B2 | Heterocyclic urea derivatives for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-20070117820-A1 | Heterocyclic urea derivatives for the treatment of pain | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-1603899-A1 | HETEROCYCLIC UREA DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004078749-A1 | HETEROCYCLIC UREA DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004024710-A1 | UREA COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117820-A1 | Heterocyclic urea derivatives for the treatment of pain | U2SURP, UMPS, SFPQ | HTR3E 2441/4885MEN1 3230/4885HTR3B 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.